



# **Isolation, Biological Characterization, and Quality Inspection of Human Umbilical Cord-derived Mesenchymal Stem Cells for Clinical Research**

**Xia Lin Zuo <sup>a,b</sup>, Wu Dongcheng <sup>c\*</sup>, Ding Yu <sup>d</sup>,  
Mohammad Auwal Sa'ad <sup>e,f</sup>, Samantha Lo Yin Teng <sup>e</sup>,  
Manickam Ravichandran <sup>f,g</sup>, Ke Xiang Ding <sup>a,h</sup>  
and Seng Kong Tham <sup>a\*</sup>**

<sup>a</sup> ALPS Medical Centre, ALPS Global Holding, Kuala Lumpur 50400, Malaysia.

<sup>b</sup> Institute of Neurosciences, Guangzhou Medical University Hospital, Guangzhou 510260, China.

<sup>c</sup> Wuhan University, Wuchang District, Wuhan, Hubei, 430072, China.

<sup>d</sup> Nanfang Southern Medical University, Southern Medical University, Guangzhou,  
Guangdong, 510515, China.

<sup>e</sup> Celestialab Sdn Bhd, Kuala Lumpur 50400, Malaysia.

<sup>f</sup> Department of Biotechnology, Faculty of Applied Sciences, AIMST University, Bedong 08100,  
Kedah, Malaysia.

<sup>g</sup> My Genome, ALPS Global Holding, Kuala Lumpur 50400, Malaysia.

<sup>h</sup> Southern Medical University of China, Guangzhou, Guangdong, 510515, China.

## **Authors' contributions**

*This work was carried out in collaboration among all authors. Authors KXD, SKT, WD and XLZ did the conceptualisation. Authors DY, KXD, SKT, WD and XLZ did the methodology. Authors KXD, SKT and XLZ did the investigation. Author SKT did the resources. Authors MAS, SLYT did the data curation. Author KXD did the writing original draft preparation. Authors MAS, SLYT, MR, and SKT did the writing review and editing. Authors SKT and KXD did the supervision. Author SKT did the funding acquisition. All authors read and approved the final manuscript.*

## **Article Information**

DOI: 10.9734/AJBGMB/2024/v16i4371

## **Open Peer Review History:**

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here:  
<https://www.sdiarticle5.com/review-history/113982>

**Original Research Article**

**Received: 01/01/2024**

**Accepted: 05/03/2024**

**Published: 19/03/2024**

## ABSTRACT

Background: Human umbilical cord mesenchymal stem cells (hUCMSCs) represent a valuable and versatile cell type derived from the umbilical cord tissue of newborns. These cells exhibit diverse characteristics, including multipotent differentiation potential and low immunogenicity. hUCMSCs hold promise for clinical applications, yet concerns persist regarding their chromosomal stability. This study employs short tandem repeat (STR) analysis to assess genomic integrity. By focusing on chromosomal stability, the study aims to enhance confidence in the clinical viability of hUCMSCs, contributing to their safe and effective use in regenerative medicine. hUCMSCs were extracted from healthy newborn umbilical cords using tissue block adherence and enzyme digestion. The third generation of hUCMSCs undergoes biological characterization and quality checks, including examinations of cell morphology, viability, growth curves, surface markers, cell cycle, and multi-lineage differentiation potential. The result of the present study shows that hUCMSCs exhibit mesenchymal stem cell characteristics, with robust growth and high viability. Positive surface markers are expressed at rates exceeding 95%, while negative markers are  $\leq 2\%$ . Cell karyotyping analysis, STR spectrum identification, and chromosomal microarray analysis confirm genetic stability. Microbial testing shows the absence of contaminants, and immunological studies demonstrate the immunomodulatory capabilities of hUCMSCs. Specific residues, such as trypsin, were not detected. In conclusion, hUCMSCs produced under strict GLP and GMP conditions meet the quality guidelines for clinical application in various stem cell therapies. The findings support the clinical application of hUCMSCs in various medical contexts.

**Keywords:** Human umbilical cord mesenchymal stem cells; Wharton's jelly stem cells; umbilical cord blood and genetic stability.

## 1. INTRODUCTION

The umbilical cord, a vital conduit between the fetal embryo and the mother's placenta, represents a unique and valuable biological resource [1]. The recycling of healthy newborn umbilical cords holds paramount significance as a precious biological resource. Moreover, within the umbilical cord tissue, specifically in Wharton's jelly, an extraordinary reservoir of stem cells exists in human umbilical cord mesenchymal stem cells (hUCMSCs) [2]. These hUCMSCs, isolated from Wharton's jelly, exhibit biological characteristics like stromal cells and bone marrow-derived Mesenchymal Stem Cells. Notably, hUCMSCs display traits closer to primitive cells, demonstrating robust proliferation and differentiation capabilities [3]. Through in vitro modulations, these cells can differentiate into osteoblasts, adipocytes, and chondrocytes. Beyond their regenerative potential, hUCMSCs possess immunosuppressive functions and support hematopoiesis [4].

Unlike other tissue-derived MSCs, the isolation process of UCMSCs is notably straightforward. The hUCMSCs express high levels of positive surface markers such as Integrin beta-1 (ITGB1) (CD29), Human Leukocyte Antigen-DR isotype (HLA-DR), 5'-nucleotidase (5'-NT) (CD73), Thy-1 (CD90), Endoglin (CD105), and CD166, while

showing minimal expression of endothelial and hematopoietic stem cell markers [5]. The potential applications of hUCMSCs extend to multiple medical conditions, such as ischemic heart disease, heart failure, cerebral infarction, liver fibrosis, pulmonary fibrosis, renal function injury, diabetes, Parkinson's syndrome, senile dementia, osteoarthritis, autoimmune diseases, tissue trauma repair, and ageing [6]. The ability of MSCs to secrete functional exosomes and vascular endothelial growth factor (VEGF) demonstrates their pivotal role in angiogenesis, myocardial precursor cell proliferation, and resistance to myocardial fibrosis [7]. Beyond these applications, MSCs exhibit promise in alleviating movement disorders, cerebellar atrophy, and interventions in ataxia models [8].

The present study aimed to comprehensively investigate the preparation of hUCMSCs for clinical applications, emphasizing their biological characteristics and standardized quality inspection. The objectives are to prepare hUCMSC, identify key biological characteristics, determine their genetic stability, and conduct quality inspections. This study seeks to contribute valuable insights to the field of regenerative medicine, providing a foundation for the safe and effective clinical application of hUCMSCs in diverse medical conditions.

## 2. MATERIALS AND METHODS

The following instrumentations, reagents, and kits were employed to ensure precision, reproducibility, and reliability of results:

Electron Microscope, Inverted Optical Microscope, and Inverted Phase Contrast Microscope (Olympus, Japan). PCR Instrument, Fluorescence Quantification PCR Instrument (Bio Molecular Systems, Australia), ABI 3730xl Genetic Analyzer (Applied biosystem, USA), UV-Visible Spectrophotometer (Agilent Technologies, USA). Flow Cytometry (BD Biosciences, USA). Cell Counter (Invitrogen, USA). ELISA Plate Reader (Agilent Technologies, USA).

Cell Culture Media and Reagents: Clinical Grade DMEM/F12 Complete Serum-Free Medium (Gibco, USA), Complete Serum-Free Medium (Stem Cell Technologies, CA), Complete Serum-Free Medium (Life Technologies, USA), Fetal Bovine Serum (Gibco, USA), Human Platelet Lysate Collagenase II, Collagenase IV, Hyaluronidase DNA Enzyme (Sigma, USA), Trypsin-EDTA (Invitrogen, USA), High-Quality Fetal Bovine Serum (USA Gibco), TrypLE/EDTA (Gibco, USA) Trypan Blue Staining Solution (Gibco, USA) Penicillin and Streptomycin Solution (Gibco, USA), Cell Culture Grade Dimethyl Sulfoxide (Sigma, USA), Calcium-Free Phosphate Buffer DPBS (Hyclone, USA), Phosphate Buffer PBS (Sinopharm, China), Adipogenic, Chondrogenic, and Osteogenic Induction Media; 3-Isobutyl-1-Methylxanthine (IBMX), L-Glutamine,  $\beta$ -Sodium Glycerophosphate, Dexamethasone, Ascorbic Acid, Insulin, Indomethacin (Sigma, USA), Alizarin Red (Schmid, Germany), Oil Red (Sinopharm, China), Alamar Blue (Life Technologies, USA), Phycoerythrin (PE) for Characteristic Surface Markers of Mesenchymal Stem Cells (CD14-PE, CD45-PE, CD34-PE, CD29-PE, CD90-PE, HLA-DR, CD105, Anti-human IgG (BD, Biosciences USA).

**Informed Consent:** Before sample collection, the parent(s) of the donor were provided with informed consent, clearly understanding the purpose, procedures, and potential implications of the donation. The consent process ensures transparency and respect for the autonomy of the donor's parent(s).

**Sample Origin and Donor Criteria:** The umbilical cords were obtained from a healthy

pregnant woman who delivered by (caesarean section) at full-term pregnancy. The study was conducted per the Declaration of Helsinki. The Donors must meet specific health criteria, ensuring the absence of congenital disorders, genetic diseases, autoimmune diseases, infectious diseases, or malignant tumour diseases. Additionally, donors undergo thorough health inspections, including negative results for HBV antigen, anti-HCV antibody, anti-HIV antibody, anti-Treponema pallidum antibody, mycoplasma, and anti-CMV antibodies.

### 2.1 Collection and Isolation of hUCMSCs

It should be noted that the cells used for analysis in this study were manufactured in Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) facilities.

#### 2.1.1 Collection of neonatal umbilical cord (NUC) sample

The hUCMSCs collection was strictly adhering to aseptic operation standards consistent with routine obstetrics and gynaecology care following the previously established protocols [9], with a slight modification.

#### 2.1.2 Pretreatment method for neonatal umbilical cord (NUC) samples

In a clean bench or biosafety cabinet, the NUC was withdrawn using sterile surgical forceps and placed in a sterile petri dish. The outer epithelium is gently removed along the longitudinal axis with a sterile surgical blade and ophthalmic forceps. The inner layer was then excised, revealing the umbilical cord blood vessels surrounded by Wharton's jelly. The cleansed sample was meticulously cut into 1 cm segments with surgical scissors, and the remaining arteries and veins were removed.

Wharton's jelly was preserved and sliced into 1mm x 3mm pieces. These fragments were promptly placed into 15ml centrifuge tubes with serum-free culture medium MSCs, each containing approximately 1g of the sample for subsequent use. The above method was conducted per a previously established protocol [10].

#### 2.1.3 Isolation of hUCMSCs

The present study employed single-enzyme digestion methods (using type I collagenase,

type II collagenase, or type IV collagenase), double-enzyme digestion methods (involving type I collagenase + trypsin or Type II collagenase + hyaluronidase), and three-enzyme digestion (involving type I collagenase + hyaluronidase + trypsin) as per the previously protocol outlined by [11] with slight modifications.

#### **2.1.4 The preparation of clinical application research grade hUCMSCs**

The preparation of clinical grade hUCMSCs for research applications adhered to a systematic method following established standards [12]:

Briefly, the hUCMSCs were revived and cultured from working bank cells. The cell confluency was monitored using an inverted microscope to ensure optimal growth and health of the hUCMSCs. Cells were digested and collected using a previously outlined procedure [12].

The cell density of hUCMSCs was carefully adjusted to a concentration of  $1 \times 10^7$  cells/ml to  $2 \times 10^7$  cells/ml using physiological saline or compound electrolyte injection. A volume ratio of 0.1% human serum albumin was added dropwise to a sterile syringe, finalizing the clinical application research-grade hUCMSCs preparation. The samples were refrigerated at 4°C and infused within 6 hours, ensuring the stability and viability of the hUCMSCs for clinical applications.

### **2.2 Cell Viability**

The cell viability analysis using the Nexcelom Cellometer Mini was conducted following a standardized protocol [12].

### **2.3 The Detection and Analysis of hUCMSCs Biological Characteristics**

#### **2.3.1 Morphological observation**

The hUCMSCs were examined using an inverted microscope to analyse their morphology and growth patterns. The growth activity detection was determined using cell counting to measure hUCMSC proliferation and growth activity. The survival rate detection was determined using the trypan blue staining method in an automatic cell counter to assess viable cells and determine the survival rate [13].

#### **2.3.2 Flow cytometry**

Flow cytometry was employed to analyse the hUCMSCs cell cycle, determining DNA content with fluorescence intensity and Mod Fit LT4.1 software. The phenotypic and surface marker

detection was conducted in adherence to a previous study [14], utilizing flow cytometry for the detection and analysis of cell surface antigen molecules based on established standards.

#### **2.3.3 Cell karyotype analysis**

Cell karyotype analysis was evaluated through the chromosomal number, shape, and structure of randomly selected metaphase cells and assessed polyploidy incidence using karyotype analysis [15].

#### **2.3.4 DNA fingerprint identification**

DNA fingerprint identification was identified by extracting the DNA using the STRAtlas method, amplifying 20 different STR and sex determination loci, and analysing results with the ABI 3730xl genetic analyser and GeneMapper 3.2 software [16]. Species source and cross-contamination were determined using ATCC and DSMZ databases.

#### **2.3.5 Chromosomal microarray analysis**

Chromosomal microarray analysis was conducted to analyse for hUCMSCS using chromosomal microarray analysis. The differentiation ability detection was assessed differentiation ability through histochemical staining and morphological identification of specific cell types. The fluorescence quantification PCR was used for detecting genes associated with adipogenesis, osteogenesis, and chondrogenesis [17].

#### **2.3.6 Multi-lineage differentiation potential of hUCMSCs**

The study assessed the multi-lineage differentiation potential of hUCMSCs through adipogenic, osteogenic, and chondrogenic pathways [18]. Adipogenic differentiation was evaluated using Oil Red O staining, osteogenic differentiation with Alizarin Red staining, and chondrogenic differentiation through Alcian blue staining. These staining techniques enabled the visualization and qualitative assessment of adipocytes, osteocytes, and chondrocytes, respectively, demonstrating the versatile and tri-lineage differentiation capacity of hUCMSCs.

### **2.4 Contaminant Screening for High-Risk Agents**

The detection of microorganisms (Mycobacteria, bacteria, and viruses) was conducted using the previously established protocols [19] with slight modifications.

#### 2.4.1 Mycobacteria detection

Mycobacteria detection was performed using the Middlebrook 7H11 agar solid medium [20]. Adhering to the "Tuberculosis Laboratory Inspection Regulations" standard, cultures were considered negative if no colony growth was observed within a week.

#### 2.4.2 Bacterial and fungal detection

Membrane filtration was employed for bacteria identification and culture detection for fungal identification. Membrane filtration allowed for speedy bacterial aggregation, while the culture detection method was used for fungal detection [21].

#### 2.4.3 Mycoplasma analysis

The hUCMSCs were cultivated in tiny culture flasks, smears were prepared and examined for mycoplasma using DNA fluorescent labelling [22]. The process involved staining with a fluorescent dye, washing, and observation under a fluorescence microscope.

#### 2.4.4 Detection of Other Toxin Markers

Using the Limulus reagent gel method for endotoxin testing, the presence or absence of retroviruses through reverse transcriptase activity, infectivity testing, and electron microscope inspection were determined [23]. Various methods, including colloidal gold, fluorescent antibody, and fluorescence quantification PCR, were used to investigate human viruses. The Western blot method was employed to detect residues (trypsin).

### 2.5 Immunoregulatory Assays

The carboxyfluorescein succinimidyl ester (CFSE) dyeing method for fluorescence-labelled flow cytometry was used to detect lymphocyte proliferation [24]. CFSE dye allowed for the evaluation of proliferation inhibition by monitoring fluorescence intensity drop during cell division.

#### 2.5.1 Flow cytometry detection of lymphocyte subpopulations

The present study employed flow cytometry to identify and quantify specific lymphocyte subsets, namely TH1 (T-helper 1), TH17 (T-helper 17), and Treg (regulatory T cells). Flow cytometry allows for the precise identification and quantification of distinct lymphocyte subpopulations based on the expression of specific cell surface markers associated with

TH1, TH17, and Treg cells [25]. The utilization of flow cytometry in this context provides valuable insights into the immune profile of the studied samples, contributing to a comprehensive understanding of the immune response and regulatory mechanisms involved in the immune system.

#### 2.5.2 ELISA for lymphokine testing

Applied Enzyme-Linked Immunosorbent Assay (ELISA) technology was used to analyse lymphokines in a distinct immunoassay, providing insights into lymphokine levels present in the samples, and offering a quantitative assessment of these signalling molecules. By employing ELISA technology, the study aimed to elucidate and quantify the presence of lymphokines, contributing valuable information to the understanding of immune responses and related biological processes.

### 2.6 Statistical Analysis

All data were expressed as mean  $\pm$  standard deviation (SD). Significance differences were calculated using one-way ANOVA, and  $p < 0.05$  was considered statistically significant.

## 3. RESULTS


### 3.1 The Biological Characteristics and Identification of hUCMSCs

#### 3.1.1 Morphological characteristics of hUCMSCs


As illustrated in Fig. 1, hUCMSCs at passage 2 were observed under an inverted microscope at a magnification of 100 times (x100), displaying long spindle-shaped cells with high refraction and organized in a conventional spiral form (Fig. 1A). Passage 3 is depicted in Fig. 1B, showcasing classic adherent growth features. The identified morphological properties align with the normal cell morphology of human mesenchymal stem cells.

#### 3.1.2 Cell growth curve and cell proliferation doubling time

The viability of P5 hUCMSCs was assessed by trypsin digesting and harvesting them during the logarithmic growth phase (exceeding 70% confluence). Resuspended in DPBS, a portion was subjected to trypan blue staining, and an automatic cell counter (Nexcelom Cellometer Mini) was employed for cell detection. The observed cell viability was 99.2%. The results are given in Table 1



**Fig. 1. A-B.** The morphology of hUCMSCs under an inverted microscope (A. Day 2, B Day 3, all magnifications x100)



**Fig. 2. Cell growth curve of hUCMSCs**

*Viability assessment of P5 hUCMSCs during the logarithmic growth phase. Cell viability was determined by trypan blue staining and automatic cell counting. Viability observed: 99.2%.*

### 3.1.3 Cell viability of hUCMSCs

The hUCMSCs were cultured in a 6-well plate according to the methodological section. Daily, cells were extracted from each well, and their total count was determined, forming a growth curve for hUCMSCs. The in vitro-produced hUCMSCs were counted, revealing a doubling time of 24.5 hours, consistent with the proliferation rate of typical human mesenchymal stem cells. [26]. The viability is shown in Table 1 and Fig. 2.


### 3.1.4 Cell cycle detection and analysis of hUCMSCs

The hUCMSCs at passage 5 were cultured until reaching the logarithmic growth phase with a confluency range of 70% to 90%. Subsequently, the cells were frozen, and stained, and the fluorescence intensity of the staining was evaluated using flow cytometry. The cell cycle was analyzed by assessing DNA content with ModFit LT4.1, revealing that 82.74% of hUCMSCs were in the G0/G1 phase, as depicted in Fig. 3A.


**Table 1. Results of counting and survival rate detection of hUCMSCs before and after cryopreservation**

Sample	Count Type	Pre cryopreservation			Result Type	Result	Average Value (µm)
		Cell Number	Dilution Factor	Concentration (Cells/ML)			
P5 hUCMSCs	Number of living cells	496	2	2956000	Living cells	99.2%	17.9
P5 hUCMSCs	Dead cells	4	2	24000	dead cells	0.8%	11.6
P5 hUCMSCs	Total cell number	500	2	2980000	total cells	100%	17.7
Post-cryopreservation and revival							
P5 hUCMSCs	Number of living cells	401	2	2384000	Living cells	92.6%	17.9
P5 hUCMSCs	Dead cells	32	2	196000	dead cells	7.4%	11.6
P5 hUCMSCs	Total cell number	433	2	2580000	total cells	100%	17.7


The average value column in Table 1 represents the mean value of cells in diameter. The results represent the average values derived from statistical calculations applied to the dataset




**Fig. 3A. Results of cell cycle flow cytometry detection and analysis of hUCMSCs reveal that 82.74% of hUCMSCs were in the G0/G1 phase**



**CD105 positive expression rate 98.5%**



**The positive expression rate of CD73 is 99.7%**



**Fig. 3B. Detection and identification results of cell phenotype and surface characteristic markers of hUCMSCs**

The results show that the hUCMSCs have a positive expression rate of more than >98% for CD73, CD90, and CD105, while the positive expression rate for CD34, CD14, CD45, CD19, and HLA-DR was  $\leq 0.2\%$

### 3.1.5 Detection of cell phenotype and surface characteristic markers

hUCMSCs were subjected to flow cytometry analysis to examine and identify cell phenotype and surface marker antigen molecules, including CD73, CD90, CD105, CD34, CD45, CD14, and

HLA-DR. Fig. 3B shows that the hUCMSCs employed in this test had a positive expression rate mean greater than 98% for CD73, CD90, and CD105, while the positive expression rate for CD34, CD14, CD45, CD19, and HLA-DR was  $\leq 0.2\%$ . These outcomes are altogether consistent with previous research [27]. Positive



expression was determined to be  $\geq 95\%$  for CD73, CD90, and CD105, and  $\leq 2\%$  for CD34, CD45, CD14, CD19, and HLA-DR. The results are given in Fig. 2B.

### 3.1.6 hUCMSCs *In vitro* cell differentiation ability

The hUCMSCs can differentiate into adipocytes, osteoblasts, and chondrocytes. In the present study, this differentiation ability was confirmed by subjecting them to specific lineages using a standard protocol, followed by staining methods (Oil Red, Alizarin Red, and Alcian Blue) (Fig. 4).

### 3.1.7 The *In vitro* identification of hUCMSCs characteristic genes related to the ability to induce differentiation


Fluorescence quantification PCR was employed to assess the expression of specific genes associated with cell differentiation types in induced hUCMSCs. FABP4 for adipogenic differentiation, Runx2 for osteogenic differentiation, and COL2A1 for chondrogenic differentiation were analyzed (Fig. 5). The results indicated that, compared to the control group, the expression levels of all detected characteristic

genes related to cell differentiation types were significantly higher after culturing hUCMSCs in adipogenic, osteogenic, and chondrogenic induction systems ( $P < 0.05$ ).

### 3.1.8 Karyotype analysis and identification


In this study, hUCMSCs underwent cell passage and purification and randomly selected 1000 metaphase cells were evaluated for chromosomal number, morphology, and structure, while an additional 500 metaphase cells were examined for polyploidy. At least 50 photomicrographs of metaphase cells were taken for karyotype analysis. Results indicated that the number of chromosomally atypical cells in the hUCMSCs sample was low (Table 2), affirming the genetic stability of hUCMSCs [28].

The G-banding technique was used to analyze the karyotypes of hUCMSCs. This involves staining chromosomes with G-band dye, followed by microscopic examination and CCD (charge-coupled device) imaging for karyotype analysis (Fig. 6). Analytical results demonstrate no aberrant changes in the chromosomal structure of hUCMSCs, maintaining a normal diploid karyotype consistent with typical hUCMSCs [29].




**Fig. 4. Three staining results of hUCMSCs multilineage differentiation potential**

The first row of pictures is oil red of adipogenic differentiation dyeing: (A) Negative control; (B) Intracellular red lipid droplets show adipogenic differentiation. The second row of pictures is alizarin red staining of osteogenic differentiation; (C) Negative control; (D) Red calcium deposits show osteoblastic differentiation. The third row of images shows characteristic staining for chondrogenic differentiation; (E) Negative control; (F) Alcian blue staining showed that the microspheres showed a cartilage-like structure surrounded by a large amount of cartilage matrix



**Fig. 5. Results of detection of adipogenic, osteogenic and chondrogenic differentiation potentials of hUCMSCs**

After inducing and differentiating hUCMSCs in vitro in adipogenic, osteogenic, and chondrogenic differentiation systems. The expression levels of adipogenic, osteogenic, and chondrogenic genes were found to be significantly higher than in the control group. Statistically significant differences were observed (\*:  $P < 0.05$ ) and highly significant differences (\*\*:  $P < 0.01$ )



**Fig. 6. The standard karyotype of the hUCMSCs passage cell line of the test product**

**Table 2. Chromosome count analysis of hUCMSCs (1000 metaphase cells)**

Chromosomal Analysis	The Standard Limit of The Number of Chromosomally Abnormal Cells	Detected Number of Abnormal Chromosomal Cells in The Sample
Chromatids and chromosome breaks	47	17
Abnormal Structure	17	7
Hyperdiploid	8	6
Hypodiploid	180	95
Polyploid	30	10
<b>Crude Count of 500 Metaphase Cells</b>		
Polyploid	17	10

### 3.1.9 Short tandem repeat (STR) analysis and cell DNA fingerprint identification

To analyze the chromosomal DNA of hUCMSCs, restriction endonucleases were employed to digest the DNA, leading to the separation of DNA fragments with varying sizes. Subsequently, the repeat sequence was hybridized with a nucleic acid probe based on the consensus sequence. This process allowed us to obtain band patterns of DNA fragments specific to hUCMSCs (Table 3).

Short Tandem Repeat gene sequences (STRs), also known as microsatellites, are repetitive DNA sequences present in eukaryotic genomes [30]. In this study, DNA was extracted and 20 STR loci along with sex identification loci were amplified using the Microreader TM21 ID System. The amplified products undergo analysis with the ABI 3730xl genetic analyser, and the results are assessed using GeneMapper3.2 software. These outcomes were then compared to databases (ATCC and DSMZ) to determine the species origin of the cells and identify any cross-contamination. Genotyping results of hUCMSCs at various STR loci, including the Amelogenin locus, reveal no tri-allelic phenomenon, contamination, or cross-contamination with other human cell types [31].

### 3.1.10 hUCMSCs gene stability

The genetic stability of hUCMSCs was evaluated by assessing both cell chromosome microarray detection and chromosome karyotype detection simultaneously. In the genome-wide scan study, hUCMSCs exhibited no clinically significant gene copy number deletions, duplications, or extensive regions of homozygosity, ensuring gene stability [32]. Chromosome karyotype analysis further confirmed a normal diploid karyotype (46, XY) for the examined hUCMSCs, free from chromosome abnormalities (Fig. 6).

## 3.2 Quality Analysis

### 3.2.1 Bacteria, fungi and mycobacteria analysis

To ensure the quality and safety of hUCMSCs products, rigorous testing was conducted. Distinct tests were carried out to identify bacteria, fungi, and mycobacteria in hUCMSCs.

For Bacterial and Fungal Detection in hUCMSCs, the membrane filtering method was utilized with both negative and positive control groups established. For mycobacteria, the Middlebrook 7H10 Plate culture method was employed. Table 4 presents the results of the bacteria, fungi,

**Table 3. Genotyping results of STR loci and amelogenin loci of hUCMSCs**

hUCMSCs STR Analysis and cells DNA fingerprint identification		
Marker	Allele 1	Allele 2
D19S433	14	16.2
D5S818	11	12
D21S11	31.2	32.2
D18S51	13	15
D6S1043	18	18
AMEL	x	x
D3S1358	16	16
D13S317	9	11
D7S820	11	12
D16S539	9	11
CSF1PO	10	11
Penta D	9	12
D2S441	10	11
wxya	14	18
D8S1179	11	12
TPOX	10	11
Penta E	11	17
TH01	7	9
D12S391	19	20
D2S1338	19	23
FGA	20	24

**Table 4. Bacterial, fungal and mycobacteria examination results in hUCMSCs injection**

Test sample	Media for Bacteria and Fungi Examination	Culture temperature (°C)	Culture time (days)	Test result
hUCMSCs	Thioglycollate medium	25	14	<0.5 EU
		35	14	<0.5 EU
Negative control	Tryptone soy broth	25	14	<0.5 EU
	Thioglycollate medium	35	14	<0.5 EU
Positive control	Tryptone soy broth	25	14	<0.5 EU
	Thioglycollate fluid medium	35	14	>0.5 EU
<i>Staphylococcus aureus</i> (CMCC (B) 26003)	Tryptone soy broth	25	14	>0.5 EU

Mycobacteria Analysis			
Test sample	Culture temperature (°C)	Culture time (days)	Result
hUCMSCs	37	59	Negative
Negative control	37	59	Negative
Positive control	37	59	Positive
<i>Mycobacterium phlei</i> (CGMCC4.1180)			

**Table 5. Mycoplasma detection results in hUCMSCs injection**

Sample	Cultivation type	Medium type	Culture temperature (°C)	Observation time (days)	Result
hUCMSCs	Primary culture	solid medium	37	21	Negative
		liquid medium		21	Negative
	Subculture	solid medium	21	Negative	
		liquid medium	21	Negative	

**Table 6. hUCMSCs of DNA fluorescent staining test results**

Samples	Culture Time	Result
hUCMSCs	7 days	Negative
negative control	7 days	Negative
positive control	3 days	Positive

**Table 7. hUCMSCs endotoxin test results**

Serial Number	Cells	Limulus Reagent Method	
		observation time	Result
1	hUCMSCs	60minute	Negative
2	negative control	60minute	Negative
3	positive control	60minute	Positive

and mycobacteria examinations for hUCMSCs, affirming the safety (<0.5 EU) and quality status of the product.

### 3.2.2 Mycoplasma analysis

A comprehensive test for mycoplasma contamination was conducted. This examination employed two methods: cultivation and DNA fluorescence staining. Tables 5-6 present the results of the mycoplasma test for hUCMSCs, providing a comprehensive assessment of the product's quality and safety.

### 3.2.3 Bacterial endotoxin analysis

The LAL (Limulus Amebocyte Lysate) test method was employed to identify bacterial endotoxin [33]. The inspection findings indicated negative results (<0.5 EU) for all bacterial endotoxin tests in the hUCMSCs (Table 7).

### 3.2.4 Virus contamination analysis

The present study assessed the internal and external viral contamination in hUCMSCs using two methods: cell morphology observation and hemadsorption test. The results obtained are presented in Table 8.

**Table 8. Observation results of cell culture morphology of hUCMSCs**

Samples	Culture Time (Days)	Result
hUCMSCs	15	normal cell morphology
Positive control (influenza virus)	2-5	CPE

Cell culture hemadsorption test results of hUCMSCs		
Test Sample	0.2%~0.5% Adsorption time of chicken and guinea pig erythrocyte suspension (minutes)	Result
hUCMSCs	30	Negative
Positive control (influenza virus)	30	Positive

Note: The CPE Indicates abnormal cell morphology and cell pathological changes

**Table 9. Inspection results of chicken embryos inoculated with hUCMSCs**

Age of embryo (Days)	No. of inoculated chicken embryos	Inoculation Site	Sample Inoculation Volume (mL/Pieces)	Observation Days	Survival Rate
9~11	10pieces	Allantoic cavity	0.2	4	≥80% (Negative hemagglutination test)
5~7	10pieces	Yolk sac	0.5	5	≥80%

**Table 10. Determination results of reverse transcriptase activity of hUCMSCs**

Samples	SQ value (pU/ml)
Standard 1	$1.0 \times 10^{12}$
Standard 2	$1.0 \times 10^{11}$
Standard 3	$1.0 \times 10^{10}$
Standard 4	$1.0 \times 10^9$
Standard 5	$1.0 \times 10^8$
Standard 6	$1.0 \times 10^7$
Sp2/0-Ag14cell	$1.68 \times 10^{10}$
hUCMSCs	—
PG-4(S+L-)cell	—
FP/RTP system control	—

Note: "—" is quantitative PCR test negative

**Table 11. Results of immunofluorescence antibody detection of hUCMSCs**

Serial Number	Detect Virus Type	Test Sample Indicator Cells	Positive Control	Negative Control	Test Sample
1	Hepatitis A virus (HAV)	Huh7	/	Negative	Negative
2	Hepatitis B virus (HBV)	Huh7	Positive	Negative	Negative
3	Hepatitis C virus (HCV)	Huh7	Positive	Negative	Negative
4	human cytomegalovirus (CMV)	2BS	/	Negative	Negative
5	human immunodeficiency virus (HIV)	Jurkat	/	Negative	Negative
6	Epstein-Barr virus	293	Positive	Negative	Negative

Furthermore, the in vivo inoculation method of chicken embryos was used for the inspection of internal and external viral contamination in hUCMSCs [34]. Table 9 depicts the findings of this study.

visual examination with a transmission electron microscope. The positive control used was mouse myeloma cell Sp2/0-Ag14, and the negative control was the PG-4 (S+L-) cell. Table 10 displays the findings.

Additionally, a retrovirus test was performed using the reverse transcriptase activity assay (TM-PERT technique), infectivity test, and a

No virus-like particles were found in the hUCMSCs culture similar to that of the negative control (PG-4(S+L-)cell), however, virus-like

particles were observed in the positive control (Sp2/0-Ag14cell).

### 3.2.5 Analysis of several important human infectious viruses

The analysis of significant human infectious viruses was conducted for several important human infectious viruses such as Hepatitis A, Hepatitis B, Hepatitis C, Cytomegalovirus Human immunodeficiency virus, and Epstein-Barr virus (HAV, HBV, HCV, CMV, HIV, and EBV) [35]. The data showed that all detection results of numerous key human infectious viruses in the hUCMSCs employed in this investigation were negative. Table 11 displays the test results.

The testing for the human papillomavirus (HPV) in hUCMSCs was done using a highly specific and sensitive fluorescent PCR method. All the hUCMSCs tested negative for 18 high-risk HPV strains (Fig. 5).

## 3.3 Analysis of Immune Response of hUCMSCs

### 3.3.1 The proliferation ability of human total lymphocytes

hUCMSCs have been shown to have immunological regulatory roles [36]. A test was performed using the Carboxyfluorescein succinimidyl ester (CFSE) marker on peripheral blood mononuclear cells (PBMCs) treated with mitomycin C and co-cultured with hUCMSCs to

evaluate the immunomodulatory effect of hUCMSCs on the proliferative potential of human total lymphocytes. Flow cytometry was used to determine lymphocyte proliferation. The results showed that hUCMSCs suppressed the proliferation of human lymphocytes induced by phytohemagglutinin (PHA) considerably ( $P < 0.001$ ) (Fig. 8A).

### 3.3.2 The regulation of T-cell subsets

The ability of hUCMSCs to reduce the secretion of pro-inflammatory factors is a crucial aspect of their immune modulation [37]. In an in vitro setting, hUCMSCs were co-cultured with human PBMCs, and the impact on lymphocyte secretion of pro-inflammatory factors TNF- $\alpha$  and IFN- $\gamma$  was assessed using ELISA. The findings indicated a significant reduction in TNF- $\alpha$  and IFN- $\gamma$  production by PBMCs in the presence of hUCMSCs ( $P < 0.01$ ) (Fig. 8B).

## 3.4 Trypsin Residues Analysis

The Coomassie brilliant blue detection method and the western blot method were employed to evaluate trypsin residue presence in the hUCMSCs culture media and other components. The absence of trypsin residue in the frozen cell supernatant indicated adherence to the required standards. Additionally, trypsin testing for porcine parvovirus in routinely used trypsin for in vitro culture and passage of hUCMSCs yielded negative results (Fig. 9).






Fig. 7. Human papillomavirus amplification curve




**Fig. 8A. Inhibition experiment of hUCMSCs on lymphocyte proliferation**

Note: hUCMSCs were treated with CFSE-labeled PBMC mitomycin C. Flow cytometry was utilized to detect lymphocyte proliferation after co-culture. A. PBMCs Blank control group; B. PBMC+hUCMSCs co-cultivation, no PHA Stimulate; C. PBMC+PHA positive control group; D. PBMC+ hUCMSCs +PHA; E. Lymphocyte proliferation index (PI) Compare. The cell proliferation index of each group was calculated using ModFit, and hUCMSCs stimulated lymphocyte proliferation was considerably inhibited (\*\*P<0.001)



**Fig. 8B. hUCMSCs inhibited the secretion of inflammatory cytokines in peripheral blood lymphocytes**

Note: Co-culturing hUCMSCs with PBMCs significantly reduces the secretion of inflammatory factors (TNF-α, IFN-γ) by PBMCs (\*\*: P<0.01)



**Fig. 9. Detection results of residual trypsin in the centrifuged supernatant of hUCMSCs**

Note: The target protein molecular weight is 23.8KD

#### 4. DISCUSSION

In the past years, two main procedures have been employed for hUCMSCs extraction: the tissue block attachment approach, which yields low-purity hUCMSCs and poses challenges for large-scale manufacture, and the enzymatic digestion and isolation approach, which employs digestive enzymes to break down tissue, reducing culture time and increasing output and purity [38].

Achieving optimal separation effects in the umbilical cord enzyme digestion and separation procedure hinges on identifying suitable digestive enzymes with precise action duration and dosage. The present study examined cell morphology which is essential for the identification of hUCMSCs. Additionally, a cell growth curve was established which serves as a crucial method for assessing the absolute growth number, vitality, and biological properties of hUCMSCs during in vitro cultivation [39]. The findings of the present study highlighted that hUCMSCs exhibit a robust expansion ability, as evidenced by the cell growth curve and cell proliferation doubling time.

Moreover, the present study determined the percentage of living cells among the total examined cells using the Trypan blue staining method. Assessing the cell survival rate is essential to identify any potential damage incurred during isolation and application. The present study measured the cell survival rate of hUCMSCs, revealing a survival rate of  $\geq 95\%$  before cryopreservation and  $\geq 85\%$  after recovery. These results agree with previously conducted research [40].

The present study employed flow cytometry to analyze the cell cycle of hUCMSCs, revealing a G0/G1 ratio of 75-85%.

The hUCMSCs represent a specific type of MSCs and their distinctive cell functions are closely tied to surface markers defining their fundamental characteristics [41]. The cell phenotypic and surface markers of hUCMSCs results demonstrated the expression of positive markers (CD73, CD90, and CD105) with mean positive rates exceeding 98%. Conversely, negative markers (CD34, CD45, CD11b, CD19, and HLA-DR) exhibited very low or no expression, with positive rates less than or equal to 0.2%. Similar findings were made by Fonseca et al., [27].

The chromosomal analysis of hUCMSCs revealed a stained karyotype consistent with 46, XX for females and 46, XY for males. The examination indicated a low count of chromosomally abnormal cells and no absence of clinically significant gene copy number deletions, duplications, or major homozygous events in MSCs. Furthermore, the present study employed STR analysis which confirms that the hUCMSCs cell line originated from a single source [42].

Chromosomal microarray analysis, a genome-wide screening technique was employed to identify chromosomal abnormalities in cells [43]. The findings of this study revealed no clinically relevant abnormalities such as gene copy number loss, duplication, or high homozygosity were detected in the chromosomes of hUCMSCs [44].

Evaluating the cells' multilineage differentiation capacity, specifically their ability to differentiate into osteocytes, adipocytes, and chondrocytes is of significant importance [45]. Using fluorescence-based PCR and differentiation kit procedures, the results demonstrated that hUCMSCs can indeed differentiate into adipogenic, osteogenic, and chondrogenic lineages, confirming the multipotent nature of hUCMSCs as noted in the previous study [46].

Microbial contamination in clinical injection medications can lead to allergies, infections, poisoning, and other complications [47]. A comprehensive test analysis was conducted to detect exogenous and associated viral agents, including bacteria, fungi, mycobacteria, mycoplasma, bacterial endotoxins, endogenous viral factors, retroviruses, and specific human viruses. The findings of this study demonstrated the absence of all the above-mentioned endotoxins ( $\leq 0.5$  EU/ml) [48], and no presence of trypsin porcine parvovirus. Retrovirus, endogenous viral factors, and specific human viruses (TP, HIV, HAV, HBV, HCV, HCMV, EBV, HPV) were also not detected. Additionally, negative findings were observed for 18 high-risk HPV. These comprehensive tests affirm the sterility and safety of the extracted hUCMSCs.

Immunological tests were conducted on hUCMSCs, specifically employing the lymphocyte proliferation inhibition assay, specific lymphocyte subsets (TH1/TH17/Treg) modulation test, and lymphokine detection test [49]. The results indicated a significant inhibition of



lymphocyte proliferation by the hUCMSCs. The modulation of specific lymphocyte subsets (TH1/TH17/Treg) demonstrated that there is an increased proportion of Tregs in lymphocytes while decreasing the ratio of TH1 to TH17, suggesting a regulatory effect on immune responses [50]. Furthermore, the ELISA technique was used to assess lymphokine secretion. The outcomes revealed that the hUCMSC preparation possesses the ability to suppress the expression and secretion of TNF- $\alpha$  and IFN- $\gamma$ , indicating an immunomodulatory capacity [51].

Besides, the analyses of trypsin levels in hUCMSC were conducted to determine the residual levels of additional added substances and the results were negative. Additional methods such as the cell culture system, immunofluorescence method, hemagglutination test, and aniline dye staining method were employed to determine the presence of porcine parvovirus. The results indicated the absence of porcine parvovirus in the trypsin preparation [52-58].

## 5. CONCLUSION

In the comprehensive examination of hUCMSCs, various assessments and analyses were conducted to elucidate their fundamental biological characteristics. The assessments covered a range of factors, including cell viability and growth activity assays, cell cycle detection, cell phenotype and surface characteristic marker detection, cell karyotype detection, cell STR and DNA fingerprint analysis, chromosomal microarray analysis, in vitro cell differentiation ability analysis, quality control analysis, as well as adhesive growth and morphological observation. The combined results from these analyses led to the conclusion that the hUCMSCs utilized in the experiment originated from a single source and exhibited the expected basic biological traits and qualities. This comprehensive evaluation provides a thorough understanding of the biological properties of hUCMSCs, ensuring their suitability for various scientific and clinical applications in line with established standards and guidelines.

## CONSENT

Before sample collection, the parent(s) of the donor were provided with written consent, clearly understanding the purpose, procedures, and potential implications of the donation. The

consent process ensures transparency and respect for the autonomy of the donor's parent.

## ACKNOWLEDGEMENTS

The authors would like to thank ALPS Global Holding Berhad for financial support and Southern Medical University of China, Guangzhou, Guangdong for assistance in completing this study.

## COMPETING INTERESTS

Authors have declared that they have no known competing financial interests OR non-financial interests OR personal relationships that could have appeared to influence the work reported in this paper.

## REFERENCES

1. Heil JR, Bordoni B. Embryology, Umbilical Cord. Stat Pearls, Treasure Island (FL): Stat Pearls Publishing; 2023.
2. Li T, Zhou L, Fan M, Chen Z, Yan L, Lu H, et al. Human umbilical cord-derived mesenchymal stem cells ameliorate skin aging of nude mice through autophagy-mediated anti-senescent mechanism. Stem Cell Rev and Rep. 2022;18:2088–103. Available: <https://doi.org/10.1007/s12015-022-10418-9>
3. Kou M, Huang L, Yang J, Chiang Z, Chen S, Liu J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis. 2022;13:1–16. Available: <https://doi.org/10.1038/s41419-022-05034-x>
4. Mosaddad SA, Rasoolzade B, Namanloo RA, Azarpira N, Dortaj H. Stem cells and common biomaterials in dentistry: A review study. J Mater Sci: Mater Med. 2022;33:55. Available: <https://doi.org/10.1007/s10856-022-06676-1>
5. Russo E, Alberti G, Corrao S, Borlongan CV, Miceli V, Conaldi PG, et al. The truth is out there: Biological features and clinical indications of extracellular vesicles from human perinatal stem cells. Cells. 2023;12:2347. Available: <https://doi.org/10.3390/cells12192347>
6. Ebrahimi A, Ahmadi H, Ghasrodashti ZP, Tanideh N, Shahriarirad R, Erfani A, et al. Therapeutic effects of stem cells in

- different body systems, a novel method that is yet to gain trust: A comprehensive review. *Bosn J Basic Med Sci.* 2021;21:672–701.  
Available:<https://doi.org/10.17305/bjbms.2021.5508>.
7. Ahmed L, Al-Massri K. New approaches for enhancement of the efficacy of mesenchymal stem cell-derived exosomes in cardiovascular diseases. *Tissue Eng Regen Med.* 2022;19:1129–46.  
Available:<https://doi.org/10.1007/s13770-022-00469-x>
  8. Park N, Sharma C, Jung UJ, Kim S, Nam Y, Kim K-S, et al. Mesenchymal stem cell transplantation ameliorates ara-c-induced motor deficits in a mouse model of cerebellar ataxia. *Journal of Clinical Medicine.* 2023;12:1756.  
Available:<https://doi.org/10.3390/jcm12051756>
  9. Wang J, Gao S, Zhao Y, Fan T, Zhang M, Chang D. Manufacture and quality control of human umbilical cord-derived mesenchymal stem cell sheets for clinical use. *Cells.* 2022;11:2732.  
Available:<https://doi.org/10.3390/cells11172732>.
  10. Xie Y, Yao J, Yan M, Lin Y, Wei J, Wang H, et al. Pretreatment of UC-MSCs with IFN- $\alpha$ 2 improves treatment of liver fibrosis by recruiting neutrophils. *Journal of Translational Medicine.* 2023;21:832.  
Available:<https://doi.org/10.1186/s12967-023-04732-0>
  11. Yi X, Chen F, Liu F, Peng Q, Li Y, Li S, et al. Comparative separation methods and biological characteristics of human placental and umbilical cord mesenchymal stem cells in serum-free culture conditions. *Stem Cell Research & Therapy.* 2020;11:183.  
Available:<https://doi.org/10.1186/s13287-020-01690-y>
  12. Xie Y, Liu W, Liu S, Wang L, Mu D, Cui Y, et al. The quality evaluation system establishment of mesenchymal stromal cells for cell-based therapy products. *Stem Cell Res Ther.* 2020;11:176.  
Available:<https://doi.org/10.1186/s13287-020-01696-6>
  13. Wang L, Wang J, Zhou X, Sun J, Zhu B, Duan C, et al. A new self-healing hydrogel containing hucMSC-derived exosomes promotes bone regeneration. *Frontiers in Bioengineering and Biotechnology.* 2020;8.
  14. Guo R, Wan F, Morimatsu M, Xu Q, Feng T, Yang H, et al. Cell sheet formation enhances the therapeutic effects of human umbilical cord mesenchymal stem cells on myocardial infarction as a bioactive material. *Bioactive Materials.* 2021;6:2999–3012.  
Available:<https://doi.org/10.1016/j.bioactmat.2021.01.036>
  15. Wu J, Huang Q-M, Liu Y, Zhou J, Tang W-R, Wang X-Y, et al. Long-term hypoxic hUCMSCs-derived extracellular vesicles alleviates allergic rhinitis through triggering immunotolerance of their VEGF-mediated inhibition of dendritic cells maturation. *International Immunopharmacology.* 2023;124:110875.  
Available:<https://doi.org/10.1016/j.intimp.2023.110875>
  16. Basu A, Munir S, Mulaw MA, Singh K, Crisan D, Sindrilaru A, et al. A novel S100A8/A9 induced fingerprint of mesenchymal stem cells associated with enhanced wound healing. *Sci Rep.* 2018;8:6205.  
Available:<https://doi.org/10.1038/s41598-018-24425-9>
  17. Wu Y, Yang J, Ai Z, Yu M, Li J, Li S. Identification of key genes and transcription factors in aging mesenchymal stem cells by DNA microarray data. *Gene.* 2019;692:79–87.  
Available:<https://doi.org/10.1016/j.gene.2018.12.063>
  18. Ren X, Zhuang H, Zhang Y, Zhou P. Cerium oxide nanoparticles-carrying human umbilical cord mesenchymal stem cells counteract oxidative damage and facilitate tendon regeneration. *J Nanobiotechnol.* 2023;21:359.  
Available:<https://doi.org/10.1186/s12951-023-02125-5>
  19. Pakzad M, Hassani SN, Abbasi F, Hajizadeh-Saffar E, Taghiyar L, Fallah N, et al. A roadmap for the production of a GMP-compatible cell bank of allogeneic bone marrow-derived clonal mesenchymal stromal cells for cell therapy applications. *Stem Cell Rev and Rep.* 2022;18:2279–95.  
Available:<https://doi.org/10.1007/s12015-022-10351-x>
  20. Yudintceva N, Mikhailova N, Bobkov D, Yakovleva L, Nikolaev B, Krasavina D, et al. Evaluation of the biodistribution of mesenchymal stem cells in a pre-clinical renal tuberculosis model by non-linear

- magnetic response measurements. *Frontiers in Physics*. 2021;9.
21. Vatsa P, Jahan S, Ansari UA, Khan A, Mir SA, Alshehri B, et al. Stem cell safety and sterility testing: A promising approach in regenerative medicine. In: Khan FA, editor. *Stem Cell Production: Processes, Practices and Regulations*, Singapore: Springer. 2022;205–32. Available: [https://doi.org/10.1007/978-981-16-7589-8\\_9](https://doi.org/10.1007/978-981-16-7589-8_9)
  22. Jacob A, Vedaie M, Roberts DA, Thomas DC, Villacorta-Martin C, Alysandratos K-D, et al. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells. *Nat Protoc*. 2019;14:3303–32. Available: <https://doi.org/10.1038/s41596-019-0220-0>
  23. Ballikaya S, Sadeghi S, Niebergall-Roth E, Nimtz L, Frindert J, Norrick A, et al. Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: Off-the-shelf GMP-manufactured donor-independent ATMP. *Stem Cell Research & Therapy*. 2020;11:482. Available: <https://doi.org/10.1186/s13287-020-01987-y>
  24. Shin H, Kwak M, Geol Lee T, Youn Lee J. Quantifying the level of nanoparticle uptake in mammalian cells using flow cytometry. *Nanoscale*. 2020;12:15743–51. Available: <https://doi.org/10.1039/D0NR01627F>
  25. Botafogo V, Pérez-Andres M, Jara-Acevedo M, Bárcena P, Grigore G, Hernández-Delgado A, et al. Age distribution of multiple functionally relevant subsets of CD4+ T Cells in human blood using a standardized and validated 14-color euroflow immune monitoring tube. *Frontiers in Immunology*. 2020;11.
  26. Bhat S, Viswanathan P, Chandanala S, Prasanna SJ, Seetharam RN. Expansion and characterization of bone marrow derived human mesenchymal stromal cells in serum-free conditions. *Sci Rep*. 2021;11:3403. Available: <https://doi.org/10.1038/s41598-021-83088-1>
  27. Fonseca LN, Bolívar-Moná S, Agudelo T, Beltrán LD, Camargo D, Correa N, et al. Cell surface markers for mesenchymal stem cells related to the skeletal system: A scoping review. *Heliyon*. 2023;9:e13464. Available: <https://doi.org/10.1016/j.heliyon.2023.e13464>
  28. Vaz IM, Borgonovo T, Kasai-Brunswick TH, Santos DS dos, Mesquita FCP, Vasques JF, et al. Chromosomal aberrations after induced pluripotent stem cells reprogramming. *Genet Mol Biol*. 2021;44:e20200147. Available: <https://doi.org/10.1590/1678-4685-GMB-2020-0147>
  29. Yang W, Zhang J, Xu B, He Y, Liu W, Li J, et al. HucMSC-Derived Exosomes Mitigate the age-related retardation of fertility in female mice. *Molecular Therapy*. 2020;28:1200–13. Available: <https://doi.org/10.1016/j.ymthe.2020.02.003>
  30. Nwawuba Stanley U, Mohammed Khadija A, Bukola AT, Omusi Precious I, Ayevbomwan Davidson E. Forensic DNA Profiling: Autosomal Short Tandem Repeat as a Prominent Marker in Crime Investigation. *Malays J Med Sci*. 2020;27:22–35. Available: <https://doi.org/10.21315/mjms2020.27.4.3>
  31. Siemionow M, Szilagyi E, Cwykiel J, Domaszewska-Szostek A, Heydemann A, Garcia-Martinez J, et al. Transplantation of dystrophin expressing chimeric human cells of myoblast/mesenchymal stem cell origin improves function in duchenne muscular dystrophy model. *Stem Cells and Development*. 2021;30:190–202. Available: <https://doi.org/10.1089/scd.2020.0161>
  32. Struijk RB, Dorssers LCJ, Henneman P, Rijlaarsdam MA, Venema A, Jongejan A, et al. Comparing genome-scale DNA methylation and CNV marks between adult human cultured ITGA6+ testicular cells and seminomas to assess *In vitro* genomic stability. *Plos One*. 2020;15:e0230253. Available: <https://doi.org/10.1371/journal.pone.0230253>
  33. Dubczak J, Reid N, Tsuchiya M. Evaluation of limulus amoebocyte lysate and recombinant endotoxin alternative assays for an assessment of endotoxin detection specificity. *European Journal of Pharmaceutical Sciences*. 2021;159:105716. Available: <https://doi.org/10.1016/j.ejps.2021.105716>
  34. Ribeiro LNM, Schlemper AE, da Silva MV, Fonseca BB. Chicken embryo: A useful

- animal model for drug testing? *Eur Rev Med Pharmacol Sci.* 2022;26:4828–39. Available:[https://doi.org/10.26355/eurrev\\_202207\\_29208](https://doi.org/10.26355/eurrev_202207_29208)
35. Baer PC, Koch B, Hickmann E, Schubert R, Cinatl J, Hauser IA, et al. Isolation, characterization, differentiation and immunomodulatory capacity of mesenchymal stromal/stem cells from human perirenal adipose tissue. *Cells.* 2019;8:1346. Available:<https://doi.org/10.3390/cells8111346>
36. Xie M, Li C, She Z, Wu F, Mao J, Hun M, et al. Human umbilical cord mesenchymal stem cells derived extracellular vesicles regulate acquired immune response of lupus mouse in vitro. *Sci Rep.* 2022;12:13101. Available:<https://doi.org/10.1038/s41598-022-17331-8>
37. Xie Q, Liu R, Jiang J, Peng J, Yang C, Zhang W, et al. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? *Stem Cell Res Ther.* 2020;11:519. Available:<https://doi.org/10.1186/s13287-020-02011-z>
38. Yi X, Chen F, Liu F, Peng Q, Li Y, Li S, et al. Comparative separation methods and biological characteristics of human placental and umbilical cord mesenchymal stem cells in serum-free culture conditions. *Stem Cell Research & Therapy.* 2020;11:183. Available:<https://doi.org/10.1186/s13287-020-01690-y>
39. Duan Y, Lyu L, Zhan S. Stem cell therapy for alzheimer's disease: A scoping review for 2017–2022. *Biomedicines.* 2023;11:120. Available:<https://doi.org/10.3390/biomedicines11010120>
40. Ellakany AR, El Baz H, Shoheib ZS, Elzallat M, Ashour DS, Yassen NA. Stem cell-derived exosomes as a potential therapy for schistosomal hepatic fibrosis in experimental animals. *Pathogens and Global Health.* 2023;0:1–21. Available:<https://doi.org/10.1080/20477724.2023.2240085>
41. Mirza A, Khan I, Qazi R-M, Salim A, Husain M, Herzig JW. Role of Wnt/ $\beta$ -catenin pathway in cardiac lineage commitment of human umbilical cord mesenchymal stem cells by zebularine and 2'-deoxycytidine. *Tissue and Cell.* 2022;77:101850. Available:<https://doi.org/10.1016/j.tice.2022.101850>
42. Silva AKA, Morille M, Piffoux M, Arumugam S, Mauduit P, Larghero J, et al. Development of extracellular vesicle-based medicinal products: A position paper of the group extracellular vesicle translation to clinical perspectives – evolve France. *Advanced Drug Delivery Reviews.* 2021;179:114001. Available:<https://doi.org/10.1016/j.addr.2021.114001>
43. Hsiao C-H, Chen J-S, Shiao Y-M, Chen Y-J, Chen C-H, Chu W-C, et al. Prenatal diagnosis using chromosomal microarray analysis in high-risk pregnancies. *Journal of Clinical Medicine.* 2022;11:3624. Available:<https://doi.org/10.3390/jcm11133624>
44. Takahashi A, Yousif A, Hong L, Chefetz Ii. Premature ovarian insufficiency: Pathogenesis and therapeutic potential of mesenchymal stem cell. *J Mol Med.* 2021;99:637–50. Available:<https://doi.org/10.1007/s00109-021-02055-5>
45. Cárdenas-León CG, Montoya-Contreras A, Mäemets-Allas K, Jaks V, Salazar-Olivo LA. A human preadipocyte cell strain with multipotent differentiation capability as an in vitro model for adipogenesis. *In Vitro Cell Dev Biol-Animal.* 2020;56:399–411. Available:<https://doi.org/10.1007/s11626-020-00468-z>
46. Zheng X, Gan S, Su C, Zheng Z, Liao Y, Shao J, et al. Screening and preliminary identification of long non-coding RNAs critical for osteogenic differentiation of human umbilical cord mesenchymal stem cells. *Bioengineered.* 2022;13:6880–94. Available:<https://doi.org/10.1080/21655979.2022.2044274>
47. Hartnett KP, Jackson KA, Felsen C, McDonald R, Bardossy AC, Gokhale RH, et al. Bacterial and Fungal Infections in Persons Who Inject Drugs — Western New York, 2017. *MMWR Morb Mortal Wkly Rep.* 2019;68:583–6. Available:<https://doi.org/10.15585/mmwr.mm6826a2>
48. Research C for DE and. Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers 2019. Available:<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-pyrogen->

- and-endotoxins-testing-questions-and-answers (accessed February 19, 2024).
49. Li L, Mussack V, Görgens A, Pepeldjiyska E, Sophie Hartz A, Aslan H, et al. The potential role of serum extracellular vesicle derived small RNAs in AML research as non-invasive biomarker. *Nanoscale Advances*. 2023;5:1691–705. Available:<https://doi.org/10.1039/D2NA00959E>
  50. Ma D, Xu K, Zhang G, Liu Y, Gao J, Tian M, et al. Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. *International Immunopharmacology*. 2019;74:105687. Available:<https://doi.org/10.1016/j.intimp.2019.105687>
  51. López-García L, Castro-Manrreza ME. TNF- $\alpha$  and IFN- $\gamma$  Participate in improving the immunoregulatory capacity of mesenchymal stem/stromal cells: Importance of Cell–Cell Contact and Extracellular Vesicles. *International Journal of Molecular Sciences*. 2021;22:9531. Available:<https://doi.org/10.3390/ijms22179531>
  52. Ivanovska A, Wang M, Arshaghi TE, Shaw G, Alves J, Byrne A, et al. Manufacturing mesenchymal stromal cells for the treatment of osteoarthritis in canine patients: Challenges and recommendations. *Frontiers in Veterinary Science*. 2022;9.
  53. Feng L, Wang Y, Fu Y, Yimamu A, Guo Z, Zhou C, et al. A simple and efficient strategy for cell-based and cell-free-based therapies in acute liver failure: hUCMSCs bioartificial liver. *Bioengineering & Translational Medicine*. 2023;8:e10552. Available:<https://doi.org/10.1002/btm2.10552>
  54. Qiao Y, Xu Z, Yu Y, Hou S, Geng J, Xiao T, et al. Single cell derived spheres of umbilical cord mesenchymal stem cells enhance cell stemness properties, survival ability and therapeutic potential on liver failure. *Biomaterials*. 2020; 227:119573. Available:<https://doi.org/10.1016/j.biomaterials.2019.119573>
  55. Dutrillaux B, Dutrillaux A-M, Salazar K, Boucher S. Multiple Chromosome Fissions, Including That of the X Chromosome, in *Aulacocyclus tricuspidis* Kaup (Coleoptera, Passalidae) from New Caledonia: Characterization of a Rare but Recurrent Pathway of Chromosome Evolution in Animals. *Genes*. 2023;14:1487. Available:<https://doi.org/10.3390/genes14071487>
  56. Mizuno M, Endo K, Katano H, Amano N, Nomura M, Hasegawa Y, et al. Transplantation of human autologous synovial mesenchymal stem cells with trisomy 7 into the knee joint and 5 years of follow-up. *Stem Cells Translational Medicine*. 2021;10:1530–43. Available:<https://doi.org/10.1002/sctm.20-0491>
  57. Fotsing SF, Margoliash J, Wang C, Saini S, Yanicky R, Shleizer-Burko S, et al. The impact of short tandem repeat variation on gene expression. *Nat Genet*. 2019;51:1652–9. Available:<https://doi.org/10.1038/s41588-019-0521-9>
  58. Harris G, Stickland CA, Lim M, Goldberg Oppenheimer P. Raman spectroscopy spectral fingerprints of biomarkers of traumatic brain injury. *Cells*. 2023; 12:2589. Available:<https://doi.org/10.3390/cells12222589>

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*  
The peer review history for this paper can be accessed here:  
<https://www.sdiarticle5.com/review-history/113982>